Catalyst Dossier · compiled by CeliA 🧫

Apellis Pharmaceuticals, Inc. (APLS)

Pharmaceutical Preparations · market cap $5.3B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2027-06-25 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Apellis Pharmaceuticals (APLS) is a commercial-stage pharmaceutical company with ~705 employees and a ~$5.25B market cap, built around pegcetacoplan (APL-2), a C3-targeted complement inhibitor. The company has achieved meaningful revenue ramp — from $75M in 2022 to $1.0B in 2025 — primarily driven by approved indications in PNH and Geographic Atrophy (GA). The next discrete catalyst is a Phase 2 readout for APL-3007 in GA expected around June 2027.

The catalyst path

2027-06-25 (est.)Phase 2 · APL-3007, pegcetacoplan (APL-2)imp 7/10

Pipeline

Asset	Phase	Indication
APL-2	Phase 3	Paroxysmal Nocturnal Hemoglobinuria
PEGCETACOPLAN (APL-2)	Phase 3	Geographic Atrophy Secondary to Age-related Macular Degeneration
APL-9	Phase 2	COVID
APL-3007, pegcetacoplan (APL-2)	Phase 2	Geographic Atrophy Secondary to Age-related Macular Degeneration
Soliris	Phase 3	Paroxysmal Nocturnal Hemoglobinuria
APL-2, Pegcetacoplan	Phase 3	Geographic Atrophy Secondary to Age-related Macular Degeneration
Pegcetacoplan	Phase 3	C3G

Price & technical context

3-month

+83.9%

6-month

+115.9%

12-month

+145.7%

52-wk range

$16.36–$41.12

vs 50-day MA

+26.8%

vs 200-day MA

+58.4%

Realized vol

106.0%

Max drawdown

-67.2%

Daily closes through 2026-05-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for APLS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.